|
|
Article: No letup
- Article from:
- Drug Topics
- Article date:
- March 4, 1996
- Author:
CopyrightCopyright Medical Economics Inc. Mar 4, 1996. Provided by ProQuest LLC. (Hide copyright information)
|
More CCBs on the way, despite the controversy
The recent controversy surrounding the use of calciumchannel blockers has not slowed the rate of development of new agents in this class. In fact, a number of new, and newly formulated, agents have recently been approved, or are expected to be approved soon, by the Food & Drug Administration.
Tiazac (Forest Laboratories) is one of the most recent drugs to reach the market. It is not really a new drug but rather a novel formulation of diltiazem hydrochloride. The once-a-day calcium-channel blocker is available in a wide range of doses for treatment of hypertension. Tiazac relies on an extended-release, osmotic-driven diffusion system to ...